United Therapeutics Pays $525 Million To End Royalties On Ralinepag, A Drug Whose Sole API Maker Failed An FDA Inspection
The lump sum to Pfizer's Arena unit hits fourth-quarter R&D expense, while the FDA's June 24, 2027 goal date for ralinepag hangs on a supplier fix.
United Therapeutics, which develops and sells drugs for pulmonary arterial hypertension, paid $525.0 million on November 3 to Pfizer's Arena unit to end all royalties on ralinepag, its experimental PAH pill, according to its 10-Q filed Wednesday. The drug's sole active-ingredient supplier drew a negative FDA inspection result in late September.
A lump sum to kill the royalty
The payment, funded from cash on hand, eliminates the royalty United Therapeutics owed Arena on net sales of any product containing ralinepag, including the extended-release tablets and an inhaled version if approved. The company expects to book the full $525.0 million as research and development expense in the fourth quarter.
Milestone payments to Arena remain in place: $250.0 million on the first US approval of an inhaled ralinepag, and $150.0 million for the first approval of an oral version in Japan, France, Italy, the United Kingdom, Spain or Germany. The prior arrangement also carried a low double-digit, tiered royalty, which is what the new payment retires.
Total cash and marketable investments stood at $3,535.7 million on September 30, down from $4,697.0 million at December 31, 2025, before the Arena payment went out.
The supplier problem behind ralinepag
United Therapeutics relies on one contract maker, ScinoPharm Taiwan, for ralinepag's active ingredient, including the supply planned for launch. In late September the FDA labeled its inspection of ScinoPharm "Official Action Indicated," a rating that signals unacceptable compliance and possible regulatory or administrative action.
The FDA has said the deficiencies must be resolved, likely confirmed by reinspection or a preapproval inspection, before it can approve the ralinepag application. The agency accepted that application in August with a goal date of June 24, 2027. The company warns that without a compliance finding the FDA may issue a complete response letter, which could delay approval and launch.
The prior quarterly report carried no ScinoPharm warning. The new filing says qualifying a replacement source, including the company's own Silver Spring, Maryland facility, likely will not finish before the June 2027 action date.
Settlement cash and a bigger buyback
The filing also shows a Liquidia settlement that is expected to bring $330.4 million in damages, of which $185.0 million arrived in October and $145.4 million is due in two installments. Liquidia must also seek removal of the PH-ILD indication from its Yutrepia label. The company recorded a $66.5 million reversal of a Sandoz-related accrual.
The company had used up its $3.0 billion of buyback authorizations by September 30, and its board approved a new $2.0 billion program on October 21. Separately, the FDA feedback in October left its triple-combination ralinepag program paused.
Tyvaso, Remodulin and Orenitram drive the business; third-quarter revenue was $832.5 million against $799.5 million a year earlier, and research and development expense was $279.2 million against $127.5 million.
The next marker is the FDA's June 24, 2027 goal date for ralinepag, which now depends on ScinoPharm's facility clearing reinspection.
Sources
- 10-Q Filing — United Therapeutics (UTHR) — SEC EDGAR
- 10-Q Filing — United Therapeutics (UTHR), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR